TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01663402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab administered as SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to alirocumab administered as a SC injection of 1 mL in the abdomen or thigh with a disposable auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMT
Description: Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LMT
Description: Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.
Study: NCT02360514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hantavax injection
Description: Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
Study: NCT03319771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Walking Exercise Training
Description: 12-weeks of supervised, progressive treadmill walking exercise training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching-and-toning Exercise Training
Description: 12-weeks of supervised, stretching-and-toning exercise training
Study: NCT02347046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)
Description: FYU-981, (Oral single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)
Description: FYU-981, (Oral single dosing)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981, (Oral single dosing)
Description: FYU-981, (Oral single dosing)
Study: NCT02740842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal behavioral change communication
Description: This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mass media
Description: A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
Study: NCT03148262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Comfort Flo system
Description: The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: The Salter nasal cannula
Description: A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
Study: NCT01774591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azilsartan medoximil
Description: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
Study: NCT01159574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40mg will be given on days 1, 8, 15, 22 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin
Description: orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: orally 4mg daily for days 1-21 of each 28 day cycle
Study: NCT01909700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Incision Mesh
Description: Single Incision Mesh is implanted for pelvic floor reconstruction
Study: NCT02991274

Intervention type: PROCEDURE
Intervention: genomic testing of T790M mutation
Description: patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
Study: NCT01575080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour TS Blood Glucose Monitoring System
Description: Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
Study: NCT02889224

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obese

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercortisolism

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrocortisone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Study: NCT03369574

Intervention type: DRUG
Intervention: Reslizumab
Description: reslizumab administration
Study: NCT01339039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Daily administration for 5-9 days prior to surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 \& 15).
Study: NCT02112253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator ventral electrode up to 2 mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator ventral electrode up to 3 mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator dorsal electrode up to 2 mA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulator dorsal electrode up to 3 mA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulator empirical programming
Study: NCT01187316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
Study: NCT00905996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic cyanoacrylate injection
Description: Endoscopic cyanoacrylate injection in gastric varix

Intervention type: DRUG
Group type: OTHER
Intervention: Beta-blocker (propranolol)
Study: NCT03839134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe® Comfort Injection System
Description: Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe® Comfort Injection System
Description: Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DentalVibe® Comfort Injection System
Description: Soft tissue vibration for 10 seconds using DentalVibe®. The device induces approximately 16 soft tissue vibrations of per second. The device will be in touch of oral mucosa (at the site of injection) before and during the local anesthesia injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Epinephrine
Description: Dental local anesthesia injection of 1.8 mL Lidocaine (2%) with Epinephrine (1:80000 w/v).
Study: NCT03597737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pain APP
Description: pain app Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
Study: NCT02228252

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluten protein
Study: NCT03602105

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercises in group and/or individually
Study: NCT01443858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meclizine
Description: Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.~Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week.
Study: NCT04192253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin
Description: Paclitaxel 175 mg/m2 and Carboplatin AUC 5 in a 3 weekly schedule
Study: NCT01443858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
Study: NCT03588130

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EscharEx (5% EX-02 formulation)
Description: Active arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gel Vehicle
Description: Control arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical standard of care (NSSOC)
Description: Santyl (Enzymatic debridement) or commercially approved Hydrogel
Study: NCT03195439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TTP
Description: TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
Study: NCT03567473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Description: Two doses of oral dexamethasone, 0.6 mg/kg (maximum single dose 10 mg). One at the time of emergency department enrolment immediately prior to first nebulized treatment and one at approximately 24 hour later

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized Epinephrine
Description: Two nebulized treatments of 3 mL 1:1000 epinephrine 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Two doses of oral placebo, 0.6 mL/kg (maximum single dose 10 mL). One at the time of emergency department enrolment immediately prior to nebulized treatment and one at approximately 24 hour later . Oral placebo at Canadian sites is composed of OraBlendTM and in New Zealand and Australian sites will be a compounded solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nebulized normal saline
Description: Two nebulized treatments of 3 mL of normal saline 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDI Epinephrine
Description: Two doses of Epinephrine given by MDI plus spacer at 625 mcg (5 actuations of 125mcg) 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MDI placebo
Description: Two doses of inhaled placebo given by MDI plus spacer, 30 minutes apart (+/- 15 minutes) at the time of emergency department enrolment.
Study: NCT04817332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib
Description: Selective, competitive, and reversible inhibitor of DPP1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT03553576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low volume bolus
Description: Administration of a low-volume bolus (6.25 mL) of greater density solution (0.1% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High volume bolus
Description: Administration of a high-volume bolus (10 mL) of lower density local anesthetic (0.0625% bupivacaine with fentanyl 2.0 mcg/mL) at 250 mL per hour given by CADD pump.
Study: NCT03612583

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung- and Diaphragm-Protective Ventilation
Description: Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung- and Diaphragm-Protective Ventilation
Description: Ventilation and sedation will be progressively modified according to the LDPV algorithm to achieve targets. Patients will be crossed-over to the opposite PEEP strategy. LDPV titration will then be repeated to achieve LDPV targets. After establishing a combination of ventilation and sedation settings at which LDPV targets are achieved, the targets will be maintained over a 24-hour period.
Study: NCT03179358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-REX Ring-locking Procedure
Description: The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.~The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC
Study: NCT03255694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-somatropin
Description: After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
Study: NCT02216383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntocinon
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntometrine
Description: The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
Study: NCT01061996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
Study: NCT00666302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment
Description: topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pimecrolimus cream
Description: topical
Study: NCT00830128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
Study: NCT01090180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (sugar pill)
Description: inactive
Study: NCT04266899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot Drop Stimulator - Neuro Orthosis
Description: The WalkAide system is a self-contained functional electrical stimulation device with a built-in tilt sensor and attaches with a cuff to the leg below the knee. The device stimulates the peroneal nerve provides active dorsiflexion of muscle during the swing phase of gait.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Gait training on a treadmill
Study: NCT00846053

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET
Description: All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDG-PET
Description: All subjects underwent FDG-PET and low-dose volumetric CT imaging. After completing a transmission scan, \[18F\]FDG was injected intravenously at the start of dynamic scan acquisition. Regions of interest were drawn over multiple tomographic slices to determine average whole-lung and regional lung tissue \[18F\] FDG uptake. Patlak graphical analysis was used to determine the rate of \[18F\]FDG uptake from the blood input function and lung tissue activity curves, measured as the influx constant Ki (slope of the linear regression from the Patlak plot). Corrected Ki (i.e., Ki divided by the initial volume of distribution). Lung density was calculated from the attenuation image by standard methods.
Study: NCT04534998

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Partial nephrectomy
Description: Partial nephrectomy for localized kidney cancer as curative treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial nephrectomy
Description: Partial nephrectomy for localized kidney cancer as curative treatment.
Study: NCT01876108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.